sphingosine-1-phosphate has been researched along with Lymphedema* in 2 studies
2 other study(ies) available for sphingosine-1-phosphate and Lymphedema
| Article | Year |
|---|---|
Abnormal Lymphatic Sphingosine-1-Phosphate Signaling Aggravates Lymphatic Dysfunction and Tissue Inflammation.
Lymphedema is a global health problem with no effective drug treatment. Enhanced T-cell immunity and abnormal lymphatic endothelial cell (LEC) signaling are promising therapeutic targets for this condition. Sphingosine-1-phosphate (S1P) mediates a key signaling pathway required for normal LEC function, and altered S1P signaling in LECs could lead to lymphatic disease and pathogenic T-cell activation. Characterizing this biology is relevant for developing much needed therapies.. Human and mouse lymphedema was studied. Lymphedema was induced in mice by surgically ligating the tail lymphatics. Lymphedematous dermal tissue was assessed for S1P signaling. To verify the role of altered S1P signaling effects in lymphatic cells, LEC-specific. This study suggests that reduction of the LEC S1P signaling aggravates lymphedema by enhancing LEC adhesion and amplifying pathogenic CD4 T-cell responses. P-selectin inhibitors are suggested as a possible treatment for this pervasive condition. Topics: Animals; Humans; Inflammation; Lymphedema; Mice; P-Selectin; Signal Transduction | 2023 |
Sphingolipid Signaling Takes Center Stage in Regulation of Lymphatic-Immune Crosstalk in Lymphedema.
Topics: Humans; Inflammation; Lymphatic Vessels; Lymphedema; Sphingolipids | 2023 |